When it comes to research and development, things get very complicated, very quickly.
Without a background in science, it's tricky to make sense of all the jargon you have to traipse through...
And even then, it's nearly impossible to know what is – and what isn't – a good investment.
That's why Dr Mike Tubbs and his team are the most valuable allies you can have.
Not only does he have years of experience heading up some of the most powerful R&D departments in the world…
(Plus, he's a go-to adviser for the Department of Trade and Industry and the European Commission…)
He knows how to put it into practice – working with his team to identify those blockbuster stocks.
There's one he's eyeing as we speak.
This company is working on what he thinks is the most valuable drug currently being developed anywhere in the world.
They could generate $37bn off the back of it… which means any investor who gets in on it could make an absolute fortune.
If that sounds like it's worth looking into further…
Research Investments is a regulated product issued by Fleet Street Publications Ltd. Your capital is at risk when you invest in shares, never risk more than you can afford to lose. Please seek independent financial advice if necessary. Fleet Street Publications Ltd. 0207 633 3611.
Research Investments subscribers: log-in for the full archive of all Research Investment emails.
Not a subscriber yet? Find out more about Research Investments here.